- Home
- UBSI vs TFX Comparison
UBSI vs TFX Comparison
Compare UBSI & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBSI
- TFX
- Stock Information
- Founded
- UBSI 1982
- TFX 1943
- Country
- UBSI United States
- TFX United States
- Employees
- UBSI N/A
- TFX N/A
- Industry
- UBSI Major Banks
- TFX Medical/Dental Instruments
- Sector
- UBSI Finance
- TFX Health Care
- Exchange
- UBSI Nasdaq
- TFX Nasdaq
- Market Cap
- UBSI 5.3B
- TFX 5.3B
- IPO Year
- UBSI N/A
- TFX N/A
- Fundamental
- Price
- UBSI $37.30
- TFX $110.95
- Analyst Decision
- UBSI Hold
- TFX Hold
- Analyst Count
- UBSI 4
- TFX 10
- Target Price
- UBSI $40.13
- TFX $159.63
- AVG Volume (30 Days)
- UBSI 960.3K
- TFX 570.8K
- Earning Date
- UBSI 07-28-2025
- TFX 07-31-2025
- Dividend Yield
- UBSI 3.96%
- TFX 1.20%
- EPS Growth
- UBSI 2.88
- TFX N/A
- EPS
- UBSI 2.70
- TFX 3.20
- Revenue
- UBSI $1,021,155,000.00
- TFX $3,010,144,000.00
- Revenue This Year
- UBSI $20.44
- TFX $3.50
- Revenue Next Year
- UBSI $5.18
- TFX $5.33
- P/E Ratio
- UBSI $13.85
- TFX $35.48
- Revenue Growth
- UBSI 0.82
- TFX 0.29
- 52 Week Low
- UBSI $30.51
- TFX $110.83
- 52 Week High
- UBSI $44.43
- TFX $249.91
- Technical
- Relative Strength Index (RSI)
- UBSI 52.74
- TFX 31.88
- Support Level
- UBSI $35.97
- TFX $112.32
- Resistance Level
- UBSI $37.99
- TFX $121.75
- Average True Range (ATR)
- UBSI 0.80
- TFX 3.04
- MACD
- UBSI -0.09
- TFX -0.60
- Stochastic Oscillator
- UBSI 49.81
- TFX 0.91
About UBSI United Bankshares Inc.
United Bankshares Inc is a financial holding company that provides banking services. The company operates in one segment: Community banking, which accepts deposits, makes loans (for personal, credit card, commercial, and construction uses), provides brokerage services, safe deposit boxes, and related services.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.